SOTERA HEALTH COMPANY Net Income (Loss) Available to Common Stockholders, Basic
SOTERA HEALTH COMPANY (SHC) reported Net Income (Loss) Available to Common Stockholders, Basic of $53.64 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Income Statement › Net Income
us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic · last filed 2026-08-06
- SOTERA HEALTH COMPANY net income (loss) available to common stockholders, basic for the quarter ending 2026-06-30 was $53.64M, a 573.82% increase year-over-year.
- SOTERA HEALTH COMPANY net income (loss) available to common stockholders, basic for the quarter ending 2026-03-31 was $26.59M.
- SOTERA HEALTH COMPANY net income (loss) available to common stockholders, basic for the quarter ending 2025-12-31 was $34.85M, a 182.91% increase year-over-year.
- SOTERA HEALTH COMPANY net income (loss) available to common stockholders, basic for the quarter ending 2025-09-30 was $48.40M, a 184.91% increase year-over-year.
- SOTERA HEALTH COMPANY net income (loss) available to common stockholders, basic for fiscal 2025 was $77.94M, a 75.79% increase from fiscal 2024.
- SOTERA HEALTH COMPANY net income (loss) available to common stockholders, basic for fiscal 2024 was $44.34M, a 13.21% decline from fiscal 2023.
- SOTERA HEALTH COMPANY net income (loss) available to common stockholders, basic for fiscal 2023 was $51.09M.
- SOTERA HEALTH COMPANY net income (loss) available to common stockholders, basic for fiscal 2022 was -$233.57M, a 302.47% decline from fiscal 2021.
| Period end | Net Income (Loss) Available to Common Stockholders, Basic 3 month | Net Income (Loss) Available to Common Stockholders, Basic 6 month | Net Income (Loss) Available to Common Stockholders, Basic 9 month | Net Income (Loss) Available to Common Stockholders, Basic 12 month |
|---|---|---|---|---|
| 2026-06-30 | $53.64M 10-Q · filed 2026-08-06 | $80.23M 10-Q · filed 2026-08-06 | $115.08M derived: sum of 3 quarters · filed 2026-08-06 | $163.48M derived: sum of 4 quarters · filed 2026-08-06 |
| 2026-03-31 | $26.59M 10-Q · filed 2026-05-05 | $61.44M derived: sum of 2 quarters · filed 2026-05-05 | $109.83M derived: sum of 3 quarters · filed 2026-05-05 | $117.80M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-12-31 | $34.85M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-24 | $83.25M derived: sum of 2 quarters · filed 2026-02-24 | $91.21M derived: sum of 3 quarters · filed 2026-08-06 | $77.94M 10-K · filed 2026-02-24 |
| 2025-09-30 | $48.40M 10-Q · filed 2025-11-04 | $56.36M derived: sum of 2 quarters · filed 2026-08-06 | $43.10M 10-Q · filed 2025-11-04 | $55.42M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-06-30 | $7.96M 10-Q · filed 2026-08-06 | -$5.30M 10-Q · filed 2026-08-06 | $7.02M derived: sum of 3 quarters · filed 2026-08-06 | $24.01M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-03-31 | -$13.26M 10-Q · filed 2026-05-05 | -$943.00K derived: sum of 2 quarters · filed 2026-05-05 | $16.05M derived: sum of 3 quarters · filed 2026-05-05 | $24.79M derived: sum of 4 quarters · filed 2026-05-05 |
| 2024-12-31 | $12.32M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-24 | $29.30M derived: sum of 2 quarters · filed 2026-02-24 | $38.05M derived: sum of 3 quarters · filed 2026-02-24 | $44.34M 10-K · filed 2026-02-24 |
| 2024-09-30 | $16.99M 10-Q · filed 2025-11-04 | $25.73M derived: sum of 2 quarters · filed 2025-11-04 | $32.02M 10-Q · filed 2025-11-04 | $70.50M derived: sum of 4 quarters · filed 2026-02-24 |
| 2024-06-30 | $8.75M 10-Q · filed 2025-08-08 | $15.04M 10-Q · filed 2025-08-08 | $53.52M derived: sum of 3 quarters · filed 2026-02-24 | $39.86M derived: sum of 4 quarters · filed 2026-02-24 |
| 2024-03-31 | $6.30M 10-Q · filed 2025-05-01 | $44.77M derived: sum of 2 quarters · filed 2026-02-24 | $31.11M derived: sum of 3 quarters · filed 2026-02-24 | $54.48M derived: sum of 4 quarters · filed 2026-02-24 |
| 2023-12-31 | $38.47M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-24 | $24.81M derived: sum of 2 quarters · filed 2026-02-24 | $48.18M derived: sum of 3 quarters · filed 2026-02-24 | $51.09M 10-K · filed 2026-02-24 |
| 2023-09-30 | -$13.66M 10-Q · filed 2024-11-05 | $9.72M derived: sum of 2 quarters · filed 2024-11-05 | $12.62M 10-Q · filed 2024-11-05 | -$306.32M derived: sum of 4 quarters · filed 2025-02-27 |
| 2023-06-30 | $23.38M 10-Q · filed 2024-08-05 | $26.20M 10-Q · filed 2024-08-05 | -$292.66M derived: sum of 3 quarters · filed 2025-02-27 | -$267.79M derived: sum of 4 quarters · filed 2025-02-27 |
| 2023-03-31 | $2.82M 10-Q · filed 2024-05-02 | -$316.03M derived: sum of 2 quarters · filed 2025-02-27 | -$291.17M derived: sum of 3 quarters · filed 2025-02-27 | -$261.06M derived: sum of 4 quarters · filed 2025-02-27 |
| 2022-12-31 | -$318.86M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-27 | -$293.99M derived: sum of 2 quarters · filed 2025-02-27 | -$263.88M derived: sum of 3 quarters · filed 2025-02-27 | -$233.57M 10-K · filed 2025-02-27 |
| 2022-09-30 | $24.87M 10-Q · filed 2023-11-01 | $54.98M derived: sum of 2 quarters · filed 2023-11-01 | $85.29M 10-Q · filed 2023-11-01 | $120.84M derived: sum of 4 quarters · filed 2024-02-27 |
| 2022-06-30 | $30.11M 10-Q · filed 2023-08-03 | $60.41M 10-Q · filed 2023-08-03 | $95.97M derived: sum of 3 quarters · filed 2024-02-27 | $123.08M derived: sum of 4 quarters · filed 2024-02-27 |
| 2022-03-31 | $30.30M 10-Q · filed 2023-05-03 | $65.86M derived: sum of 2 quarters · filed 2024-02-27 | $92.97M derived: sum of 3 quarters · filed 2024-02-27 | $134.99M derived: sum of 4 quarters · filed 2024-02-27 |
| 2021-12-31 | $35.56M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-27 | $62.66M derived: sum of 2 quarters · filed 2024-02-27 | $104.69M derived: sum of 3 quarters · filed 2024-02-27 | $115.36M 10-K · filed 2024-02-27 |
| 2021-09-30 | $27.10M 10-Q · filed 2022-11-02 | $69.13M derived: sum of 2 quarters · filed 2022-11-02 | $79.80M 10-Q · filed 2022-11-02 | $36.13M derived: sum of 4 quarters · filed 2023-02-28 |
| 2021-06-30 | $42.02M 10-Q · filed 2022-08-04 | $52.70M 10-Q · filed 2022-08-04 | $9.03M derived: sum of 3 quarters · filed 2023-02-28 | $9.04M derived: sum of 4 quarters · filed 2023-02-28 |
| 2021-03-31 | $10.69M 10-Q · filed 2022-05-05 | -$32.99M derived: sum of 2 quarters · filed 2023-02-28 | -$32.98M derived: sum of 3 quarters · filed 2023-02-28 | -$25.97M derived: sum of 4 quarters · filed 2023-02-28 |
| 2020-12-31 | -$43.68M derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-28 | -$43.67M derived: sum of 2 quarters · filed 2023-02-28 | -$36.65M derived: sum of 3 quarters · filed 2023-02-28 | -$38.62M 10-K · filed 2023-02-28 |
| 2020-09-30 | $10.00K 10-Q · filed 2021-11-10 | $7.03M derived: sum of 2 quarters · filed 2021-11-10 | $5.06M 10-Q · filed 2021-11-10 | |
| 2020-06-30 | $7.02M 10-Q · filed 2021-08-12 | $5.05M 10-Q · filed 2021-08-12 | ||
| 2020-03-31 | -$1.96M 10-Q · filed 2021-05-13 | |||
| 2019-12-31 | -$20.85M 10-K · filed 2022-03-01 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Progyny, Inc. (PGNY) | United States | $1.994B | 28.37 |
| agilon health, inc. (AGL) | United States | $1.272B | -7.76 |
| VIEMED HEALTHCARE, INC. (VMD) | United States | $0.336B | 29.92 |
| Park Dental Partners, Inc. (PARK) | United States | $0.094B | |
| BioRestorative Therapies, Inc. (BRTX) | United States | $0.064B | |
| CRYO CELL INTERNATIONAL INC (CCEL) | United States | $0.033B | -11.02 |
| MANGOCEUTICALS, INC. (MGRX) | United States | $0.010B | -0.43 |
| DAVITA INC. (DVA) | United States | $11.147B | 16.80 |